A liposome curcumin composition for assisting in improving pancreatic function and use thereof

Abstract

The application discloses a liposome curcumin composition for assisting in improving pancreatic function and application thereof, and belongs to the technical field of natural compositions. The composition is composed of 60-80nm liposome curcumin powder, inulin, rice bran-derived alpha-amylase inhibitor, chromium picolinate and cinnamon extract, D-chiro-inositol, does not contain active ingredients of traditional Chinese medicines, does not have the effects of assisting in controlling blood sugar and regulating kidney, and is unique in technical targeting. The liposome curcumin is prepared by using food-grade phospholipids, has a particle size of 60-80nm, an encapsulation rate of greater than or equal to 80%, and ethanol residue of less than or equal to 0.5 ‰, is stable in the stomach and is released in the intestines in a targeted manner. The application targets the improvement of pancreatic metabolic function through the synergistic effect of three pathways of anti-inflammatory protection of pancreas, carbon blockage and insulin sensitization. The composition can be prepared into oral liquid, solid beverage, microcapsule powder or tablet, has high safety and excellent bioavailability, and is suitable for the daily maintenance of people with impaired pancreatic metabolic function.

Description

Technical Field

[0001] This invention belongs to the field of natural composition technology, and specifically relates to a liposomal curcumin composition that helps improve pancreatic function and its application. Background Technology

[0002] With changes in modern dietary structures and lifestyles, long-term high-sugar, high-fat diets, irregular sleep patterns, and metabolic imbalances have become common phenomena. These adverse factors directly lead to a continuous increase in the burden on the pancreas, resulting in impaired pancreatic metabolic function. As an important digestive and metabolic organ, pancreatic dysfunction initially manifests as exocrine abnormalities, including pancreatic enzyme secretion disorders and increased pancreatic duct pressure. Long-term progression leads to endocrine dysfunction, resulting in pathological states such as abnormal carbohydrate metabolism and decreased insulin sensitivity. Clinical data shows that the proportion of subclinical abnormalities in pancreatic metabolic function among adults in my country has exceeded 35%, and this trend is showing a younger age of onset. This makes pancreatic health maintenance a key research direction in the field of nutrition and health.

[0003] Existing technologies for pancreatic conditioning products suffer from three main drawbacks: First, the technological boundaries are blurred. Most products simultaneously claim multiple effects such as lowering blood sugar, protecting the kidneys, and protecting the liver, lacking clear targeting and failing to focus on improving the physiological functions of the pancreas itself. Second, the safety of the formulations is insufficient. Many products add active ingredients from traditional Chinese medicine (such as astragalus, coptis, and kudzu root), which, while having certain conditioning effects, may lead to metabolic burden on the liver and kidneys with long-term use, and some people may experience allergic reactions, resulting in poor compatibility. Third, the bioavailability of the core ingredients is low. Although natural curcumin has been proven to have excellent anti-inflammatory and repairing activity and can reduce pancreatic oxidative stress damage by inhibiting the NF-κB inflammatory pathway, it has poor water solubility, low intestinal absorption (oral bioavailability is less than 5%), and is easily metabolized by the liver, making it difficult to achieve an effective concentration in pancreatic tissue.

[0004] Specifically, the limitations of existing pancreas-related products are as follows: Firstly, compound Chinese medicine products must adhere to the principles of TCM syndrome differentiation and treatment, and the dosage is difficult to control precisely in ordinary food form. Furthermore, the hot and cold properties of the Chinese medicine components may conflict with individual constitutions. Secondly, single-component products (such as ordinary curcumin preparations) lack synergistic effects and cannot form a complete pancreas maintenance pathway, only achieving localized regulation. In addition, some products illegally add Western medicine ingredients (such as metformin and glibenclamide), posing serious safety risks. It is worth noting that there are currently no pure food ingredient compositions specifically targeting the pancreas's "anti-inflammatory repair-burden reduction-functional optimization" triple pathway, and there is a lack of technology for modifying curcumin with 60-80nm food-grade phospholipid liposomes, making it difficult to guarantee the effectiveness of targeted pancreas maintenance.

[0005] Therefore, developing a pancreatic care composition with clear technical boundaries (focusing solely on improving pancreatic function), a safe formula (pure food ingredients without Chinese medicine), high bioavailability of core components (60-80nm liposomal curcumin), and a clearly defined pathway of action has become a technical problem to be solved in this field. Summary of the Invention

[0006] In view of this, the present invention provides a liposomal curcumin composition and its application to help improve pancreatic function, so as to solve or alleviate one of the technical problems existing in the prior art, and at least provide a beneficial alternative.

[0007] The technical solution of this invention is implemented as follows: a composition for assisting in improving pancreatic function, comprising the following components: 60-80nm liposomal curcumin powder, inulin, rice bran-derived α-amylase inhibitor, chromium picolinate, cinnamon extract, D-chiral inositol; The liposomal curcumin is a food-grade phospholipid biomimetic liposome with a particle size of 60-80 nm, an encapsulation rate of ≥80%, and a finished product ethanol residue of ≤0.5‰. The composition does not contain any active ingredients of traditional Chinese medicine for therapeutic purposes, nor does it have the effect of assisting in controlling blood sugar or regulating the kidneys. The technology is specifically targeted at improving pancreatic function. The purity of the rice bran-derived α-amylase inhibitor is ≥85%; the coumarin content in the cinnamon extract is ≤0.5%; The content of each component is calculated per 50ml oral liquid dosage form as follows: Liposome curcumin powder 150-200mg, inulin 12-18g, rice bran-derived α-amylase inhibitor 80-120mg, chromium pyridinecarboxylate (calculated as chromium) 120-180μg, cinnamon extract 350-450mg, D-chiral inositol 250-350mg.

[0008] Furthermore, the food-grade phospholipids of the liposomal curcumin are selected from one or a combination of soybean phospholipids, egg yolk phospholipids, and the mass ratio of phospholipids to cholesterol is 2:1 to 4:1. The liposomal curcumin exhibits a release rate of less than 33% in simulated gastric fluid at pH 2.0 and a release rate of more than 80% in simulated intestinal fluid at pH 7.4 within 2 hours, with a particle size distribution span ≤ 0.5 and an absolute zeta potential ≥ 30 mV.

[0009] Furthermore, the inulin has a degree of polymerization of 2-60, a purity of ≥95%, a moisture content of ≤5%, and an ash content of ≤0.5%. The enzyme inhibitory activity of the rice bran-derived α-amylase inhibitor is ≥500 U / mg, the heavy metal content (as Pb) is ≤0.5 mg / kg, and the arsenic content (as As) is ≤0.3 mg / kg. The chromium pyridinecarboxylate has a moisture content of ≤5% and a chromium content of ≥12%, which meets the requirements of the national food additive standard GB1903.23.

[0010] Furthermore, the cinnamon extract is obtained through supercritical fluid extraction. Prepared by extraction, with an extraction pressure of 25-35 MPa and an extraction temperature of 40-50℃. Flow rate 20-30 L / h, cinnamon polyphenol content ≥30%, volatile oil content ≥5%, solvent residue (n-hexane) ≤10 mg / kg; the optical rotation of the D-chiral inositol is +64°~+67°, and the specific rotation [α]D² is... 0 The temperature is +65°±1°, the moisture content is ≤1%, and the residue on ignition is ≤0.1%.

[0011] Furthermore, when the composition is prepared as an oral liquid, it also contains food-acceptable pharmaceutical excipients, wherein the excipients are selected from one or more of purified water, buffers, flavoring agents, and preservatives; The buffer is a citrate-disodium hydrogen phosphate buffer solution, with the pH adjusted to 6.5-7.2; The flavoring agent is one or a combination of steviol glycosides and sucralose, added at a rate of 0.01-0.1 wt%. The preservative is one or a combination of potassium sorbate and sodium benzoate, and the amount added is 0.02-0.05 wt%.

[0012] Furthermore, when the composition is prepared as a solid beverage, it also contains food-acceptable anti-caking agents and fillers; The anti-caking agent is one or a combination of silicon dioxide and magnesium stearate, added at an amount of 0.1-0.5 wt%; the filler is one or a combination of maltodextrin and lactose, added at an amount of 1-5 wt%. The solid beverage has a moisture content of ≤5%, a solubility of ≥98% (25℃, 100ml water), a bulk density of 0.45-0.6g / ml, and an angle of repose of ≤30°.

[0013] Furthermore, when the composition is prepared as a microcapsule powder, it contains a wall material and an emulsifier; The wall material is selected from one or more of sodium octenyl succinate starch, maltodextrin, and gum arabic, and the mass ratio of the wall material to the core material is 1:1 to 3:1. The emulsifier is selected from one or a combination of glyceryl monostearate, sucrose ester, and has an HLB value of 8-16. The microcapsule powder has a microcapsule encapsulation rate of ≥90%, a moisture content of ≤5%, an angle of repose of ≤30°, good rehydration properties, and the liposome particle size remains in the range of 60-80nm after rehydration.

[0014] Furthermore, when the composition is prepared into tablets, it also contains food-acceptable compressible excipients; The compressible excipient is selected from one or more of microcrystalline cellulose, sodium carboxymethyl starch, and magnesium stearate; The microcrystalline cellulose is added as a filler at an amount of 10-30 wt%. The sodium carboxymethyl starch is added as a disintegrant at a dosage of 2-5 wt%. The magnesium stearate is added as a lubricant at a rate of 0.5-1 wt%. The tablets have a hardness of 40-60 N, a disintegration time of ≤15 min (37℃ purified water), and a friability of ≤0.5%.

[0015] Furthermore, the mechanism of action of the composition is to target and improve pancreatic function through a triple synergistic pathway: (1) Anti-inflammatory and pancreatic protection pathway: 60-80nm liposomal curcumin penetrates the pancreatic tissue biomembrane, inhibits the release of TNF-α and IL-6 inflammatory factors, reduces oxidative stress damage, and promotes the repair of pancreatic micro-damage; (2) Carbohydrate blocking pathway: Rice bran-derived α-amylase inhibitors competitively bind to α-amylase, reducing the rate of starch breakdown into glucose, reducing postprandial carbohydrate load, and alleviating pancreatic exocrine pressure; (3) Insulin sensitization pathway: Chromium pyridinecarboxylate and D-chiral inositol synergistically enhance the activity of insulin receptor tyrosine kinase, activate the PI3K / Akt signaling pathway, improve the sensitivity of peripheral tissues to insulin, and optimize the endocrine regulatory function of the pancreas.

[0016] Furthermore, the application is taken 30 minutes before meals, with a single dose equivalent to 50ml of oral liquid, and the continuous use period is no less than 4 weeks.

[0017] The embodiments of the present invention have the following advantages due to the adoption of the above technical solutions: (1) Clear technical boundaries: For the first time, the composition is clearly defined as "not having the function of assisting in blood sugar control or regulating kidney", focusing only on improving pancreatic function, avoiding the defects of the generalization of efficacy of existing products, and complying with the claims of food / health food; (2) High safety of the formula: All components are food raw materials or food and medicine homologous substances, without any active ingredients of traditional Chinese medicine, avoiding the incompatibilities of traditional Chinese medicine and the risks of long-term use, and are suitable for a wide range of people; (3) Excellent performance of core components: The encapsulation rate of curcumin in 60-80nm liposomes is ≥80%, and the gastric stability (2h release rate <33%) and intestinal release characteristics (2h release rate >80%) are significantly better than ordinary liposomes (usually particle size >100nm, encapsulation rate <60%), and the bioavailability is increased by 3-5 times; (4) Synergistic and efficient action pathways: The three pathways target the pancreas from three dimensions: “damage repair, load reduction and function optimization”, forming a closed-loop maintenance system. Animal experiments showed that after 8 weeks of continuous use, the inflammation score of pancreatic tissue decreased by 62% and the insulin sensitivity index increased by 48%. (5) Strong controllability of process parameters: The purity, content and formulation parameters of all components have clear quantitative standards (such as cinnamon extract coumarin ≤0.5%, chromium pyridine carboxylate 120-180μg / 50ml as chromium element), which ensures the stability and consistency of product quality.

[0018] The above overview is for illustrative purposes only and is not intended to be limiting in any way. In addition to the illustrative aspects, embodiments, and features described above, further aspects, embodiments, and features of the invention will become readily apparent from the accompanying drawings and the following detailed description. Attached Figure Description

[0019] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0020] Figure 1 This is a flowchart of the triple synergistic pathway of the present invention; Figure 2 This is a flow chart of the oral liquid dosage form preparation process of the present invention; Figure 3 This is a flowchart illustrating the in vivo release pathway of liposomal curcumin according to the present invention. Figure 4 This is a flowchart of the microcapsule powder preparation process of the present invention. Detailed Implementation

[0021] In the following description, only certain exemplary embodiments are briefly described. As those skilled in the art will recognize, the described embodiments can be modified in various ways without departing from the spirit or scope of the invention. Therefore, the drawings and description are considered to be exemplary in nature and not restrictive.

[0022] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings.

[0023] Example 1: Preparation and performance testing of oral liquid dosage form

[0024] 1. Raw material preparation

[0025] Weigh the following components per 50ml oral solution dose: Liposome curcumin powder: 150mg (particle size 65nm, encapsulation efficiency 82%, ethanol residue 0.4‰) Inulin: 12g (95% purity, degree of polymerization 2-60) Rice bran-derived α-amylase inhibitor: 80mg (85% purity, enzyme inhibitory activity ≥500U / mg) Chromium pyridinecarboxylate: Contains 120 μg of chromium (purity 99%, moisture ≤5%) Cinnamon extract: 350mg (coumarins 0.4%, cinnamon polyphenols ≥30%) D-Chiral Inositol: 250mg (98% purity, optical rotation +65°) 2. Preparation process (1) Pretreatment of liposomal curcumin: Add liposomal curcumin powder to 10 ml of purified water and ultrasonically disperse at 40 °C for 10 min to form a uniform dispersion; (2) Aqueous phase preparation: Inulin, rice bran-derived α-amylase inhibitor, chromium pyridinecarboxylate, and D-chiral inositol were added to 25 ml of purified water, stirred and dissolved at 60 °C, and filtered through a 200 mesh sieve; (3) Mixing and preparation: Add the liposome curcumin dispersion to the aqueous phase, then add cinnamon extract, stir evenly, and adjust the pH to 6.8 with citrate-disodium hydrogen phosphate buffer; (4) Volume adjustment and sterilization: Add water to make up to 50ml, sterilize at 121℃ for 15min, cool to room temperature, and fill into brown glass bottles to obtain the oral liquid product.

[0026] 3. Performance test data

[0027] 4. Simulate gastrointestinal fluid release behavior

[0028] 5. Stability test (accelerated test, 40℃±2℃, RH75%±5%, 3 months)

[0029] Example 2: Preparation and Performance Testing of Solid Beverage Dosage Forms

[0030] 1. Raw material preparation

[0031] Weigh the following components according to the dosage of each serving (20g) of solid beverage: Liposome curcumin powder: 200mg (particle size 75nm, encapsulation rate 85%, ethanol residue 0.3‰) Inulin: 18g (96% purity, degree of polymerization 2-60) Rice bran-derived α-amylase inhibitor: 120mg (88% purity, enzyme inhibitory activity ≥550U / mg) Chromium pyridinecarboxylate: Contains 180 μg of chromium (purity 99.5%, moisture ≤4%) Cinnamon extract: 450mg (coumarins 0.3%, cinnamon polyphenols ≥35%) D-Chiral Inositol: 350mg (99% purity, optical rotation +66°) Excipients: 1.5g maltodextrin (DE value 15), 0.3g silica (anti-caking agent) 2. Preparation process (1) Premixing: Mix liposome curcumin powder with inulin accounting for 1 / 3 of the total mass, place in a three-dimensional motion mixer, and mix for 15 min at 200 rpm; (2) Main mixing: Add the remaining inulin, rice bran-derived α-amylase inhibitor, chromium picolinate, cinnamon extract, D-chiral inositol and maltodextrin, and continue mixing for 30 min; (3) Sieving: The mixture is pulverized through an 80-mesh sieve, silicon dioxide is added, and it is mixed again for 10 minutes; (4) Packaging: It is packaged in aluminum foil composite bags, each bag weighing 20g, and sealed with nitrogen to obtain the solid beverage product.

[0032] 3. Performance test data

[0033] 4. Simulating gastrointestinal fluid release behavior after rehydration

[0034] 5. Nutritional composition analysis (per 100g product)

[0035] Example 3: Preparation and performance testing of microcapsule powder formulation

[0036] 1. Raw material preparation

[0037] Weigh the following components per 100g of microcapsule powder: Liposome curcumin powder: 180mg (particle size 70nm, encapsulation efficiency 83%, ethanol residue 0.45‰) Inulin: 15g (purity 95.5%, degree of polymerization 2-60) Rice bran-derived α-amylase inhibitor: 100mg (purity 86%, enzyme inhibitory activity ≥520U / mg) Chromium pyridinecarboxylate: Contains 150 μg of chromium (purity 99.2%, moisture ≤4.5%) Cinnamon extract: 400mg (coumarins 0.45%, cinnamon polyphenols ≥32%) D-Chiral Inositol: 300mg (98.5% purity, optical rotation +65.5°) Wall material: 12g sodium octenyl succinate starch, 20g maltodextrin, 5g gum arabic Emulsifier: 1.5g glyceryl monostearate 2. Preparation process (1) Preparation of core material dispersion: Liposome curcumin powder and cinnamon extract were added to 20 ml of purified water and ultrasonically dispersed at 40 °C for 15 min; then inulin, rice bran-derived α-amylase inhibitor, chromium pyridinecarboxylate and D-chiral inositol were added and stirred to dissolve to obtain core material dispersion; (2) Preparation of wall material solution: Add sodium octenyl succinate starch, maltodextrin, and gum arabic to 50 ml of purified water (60 °C), stir to dissolve, add glyceryl monostearate, and homogenize (10000 rpm, 5 min) to obtain wall material solution; (3) Emulsification and spray drying: The core material dispersion is slowly added to the wall material solution and stirred at 60°C for 30 min. After high-pressure homogenization (800 bar, 3 times), a stable emulsion is formed. The emulsion is then fed into a spray dryer (inlet air temperature 180°C, outlet air temperature 85°C, feed rate 20 ml / min) to collect the microcapsule powder. (4) Post-processing: The microcapsule powder is dried in a fluidized bed (40℃, 30min), passed through a 60-mesh sieve, and packaged in an aluminum foil bag filled with nitrogen to obtain the finished microcapsule powder.

[0038] 3. Performance test data

[0039] 4. Microcapsule powder rehydrated to simulate gastrointestinal fluid release behavior

[0040] 5. Microcapsule powder stability test (long-term test, 25℃±2℃, RH60%±10%, 6 months)

[0041] 6. Comparison of functional components in different dosage forms (based on the equivalent dose of 50ml oral solution)

[0042] Animal experiments to verify (taking the oral liquid of Example 1 as an example)

[0043] SPF-grade male SD rats, weighing 200±20g, were randomly divided into a control group (normal diet), a model group (high-sugar, high-fat diet induced pancreatic injury), and an experimental group (high-sugar, high-fat diet + oral solution from Example 1, administered by gavage at 1ml / 100g body weight daily), with 10 rats in each group. The intervention lasted for 8 weeks. Relevant indicators were measured after the last gavage.

[0044] The results showed that the pancreatic inflammation score of the experimental group rats was reduced by 62.1% and the insulin sensitivity index was increased by 48.3% compared with the model group, indicating that the composition of the present invention can effectively improve pancreatic inflammatory damage and optimize pancreatic metabolic function.

[0045] The above description is merely a specific embodiment of the present invention, but the scope of protection of the present invention is not limited thereto. Any person skilled in the art can easily conceive of various variations or substitutions within the technical scope disclosed in the present invention, and these should all be included within the scope of protection of the present invention. Therefore, the scope of protection of the present invention should be determined by the scope of the claims.

Claims

1. A composition for assisting in improving pancreatic function, characterized in that, It consists of the following components: 60-80nm liposomal curcumin powder, inulin, rice bran-derived α-amylase inhibitor, chromium picolinate, cinnamon extract, D-chiral inositol; The liposomal curcumin is a food-grade phospholipid biomimetic liposome with a particle size of 60-80 nm, an encapsulation rate of ≥80%, and a finished product ethanol residue of ≤0.5‰. The composition does not contain any active ingredients of traditional Chinese medicine for therapeutic purposes, nor does it have the effect of assisting in controlling blood sugar or regulating the kidneys. The technology is specifically targeted at improving pancreatic function. The purity of the rice bran-derived α-amylase inhibitor is ≥85%; the coumarin content in the cinnamon extract is ≤0.5%; The content of each component is calculated per 50ml oral liquid dosage form as follows: Liposome curcumin powder 150-200mg, inulin 12-18g, rice bran-derived α-amylase inhibitor 80-120mg, chromium pyridinecarboxylate (calculated as chromium) 120-180μg, cinnamon extract 350-450mg, D-chiral inositol 250-350mg.

2. The composition for assisting in improving pancreatic function according to claim 1, characterized in that, The food-grade phospholipids of the liposomal curcumin are selected from one or a combination of soybean phospholipids, egg yolk phospholipids, and the mass ratio of phospholipids to cholesterol is 2:1 to 4:

1. The liposomal curcumin exhibits a release rate of less than 33% in simulated gastric fluid at pH 2.0 and a release rate of more than 80% in simulated intestinal fluid at pH 7.4 within 2 hours, with a particle size distribution span ≤ 0.5 and an absolute zeta potential ≥ 30 mV.

3. The composition for assisting in improving pancreatic function according to claim 1, characterized in that, The inulin has a degree of polymerization of 2-60, a purity of ≥95%, a moisture content of ≤5%, and an ash content of ≤0.5%. The enzyme inhibitory activity of the rice bran-derived α-amylase inhibitor is ≥500 U / mg, the heavy metal content (as Pb) is ≤0.5 mg / kg, and the arsenic content (as As) is ≤0.3 mg / kg. The chromium pyridinecarboxylate has a moisture content of ≤5% and a chromium content of ≥12%, which meets the requirements of the national food additive standard GB1903.

23.

4. The composition for assisting in improving pancreatic function according to claim 1, characterized in that, The cinnamon extract was obtained through supercritical fluid processing. Prepared by extraction, with an extraction pressure of 25-35 MPa and an extraction temperature of 40-50℃. Flow rate 20-30 L / h, cinnamon polyphenol content ≥30%, volatile oil content ≥5%, solvent residue (n-hexane) ≤10 mg / kg; the optical rotation of the D-chiral inositol is +64°~+67°, and the specific rotation [α]D² is... 0 The temperature is +65°±1°, the moisture content is ≤1%, and the residue on ignition is ≤0.1%.

5. The composition for assisting in improving pancreatic function according to claim 1, characterized in that, When the composition is prepared as an oral liquid, it further contains food-acceptable pharmaceutical excipients, which are selected from one or more of purified water, buffers, flavoring agents, and preservatives. The buffer is a citrate-disodium hydrogen phosphate buffer solution, with the pH adjusted to 6.5-7.2; The flavoring agent is one or a combination of steviol glycosides and sucralose, added at a rate of 0.01-0.1 wt%. The preservative is one or a combination of potassium sorbate and sodium benzoate, and the amount added is 0.02-0.05 wt%.

6. The composition for assisting in improving pancreatic function according to claim 1, characterized in that, When the composition is prepared as a solid beverage, it also contains food-acceptable anti-caking agents and fillers; The anti-caking agent is one or a combination of silicon dioxide and magnesium stearate, added at an amount of 0.1-0.5 wt%; the filler is one or a combination of maltodextrin and lactose, added at an amount of 1-5 wt%. The solid beverage has a moisture content of ≤5%, a solubility of ≥98% (25℃, 100ml water), a bulk density of 0.45-0.6g / ml, and an angle of repose of ≤30°.

7. The composition for assisting in improving pancreatic function according to claim 1, characterized in that, When the composition is prepared as a microcapsule powder, it contains a wall material and an emulsifier; The wall material is selected from one or more of sodium octenyl succinate starch, maltodextrin, and gum arabic, and the mass ratio of the wall material to the core material is 1:1 to 3:

1. The emulsifier is selected from one or a combination of glyceryl monostearate, sucrose ester, and has an HLB value of 8-16. The microcapsule powder has a microcapsule encapsulation rate of ≥90%, a moisture content of ≤5%, an angle of repose of ≤30°, good rehydration properties, and the liposome particle size remains in the range of 60-80nm after rehydration.

8. The composition for assisting in improving pancreatic function according to claim 1, characterized in that, When the composition is prepared into tablets, it also contains food-acceptable compressible excipients; The compressible excipient is selected from one or more of microcrystalline cellulose, sodium carboxymethyl starch, and magnesium stearate; The microcrystalline cellulose is added as a filler at an amount of 10-30 wt%. The sodium carboxymethyl starch is added as a disintegrant at a dosage of 2-5 wt%. The magnesium stearate is added as a lubricant at a rate of 0.5-1 wt%. The tablets have a hardness of 40-60 N, a disintegration time of ≤15 min (37℃ purified water), and a friability of ≤0.5%.

9. The composition for assisting in improving pancreatic function according to claim 1, characterized in that, The mechanism of action of the composition is to target and improve pancreatic function through a triple synergistic pathway: (1) Anti-inflammatory and pancreatic protection pathway: 60-80nm liposomal curcumin penetrates the pancreatic tissue biomembrane, inhibits the release of TNF-α and IL-6 inflammatory factors, reduces oxidative stress damage, and promotes the repair of pancreatic micro-damage; (2) Carbohydrate blocking pathway: Rice bran-derived α-amylase inhibitors competitively bind to α-amylase, reducing the rate of starch breakdown into glucose, reducing postprandial carbohydrate load, and alleviating pancreatic exocrine pressure; (3) Insulin sensitization pathway: Chromium pyridinecarboxylate and D-chiral inositol synergistically enhance the activity of insulin receptor tyrosine kinase, activate the PI3K / Akt signaling pathway, improve the sensitivity of peripheral tissues to insulin, and optimize the endocrine regulatory function of the pancreas.

10. The use of the composition for assisting in improving pancreatic function according to any one of claims 1-8 in the preparation of food or health food for assisting in improving pancreatic function, characterized in that, The application is to be taken 30 minutes before meals, with a single dose equivalent to 50ml of oral liquid, and the continuous use period is no less than 4 weeks.

Images